Next, to evaluate the functional effect of FTO-lncAML in controlling the expression of genes within the IRX3 TAD, we performed shRNA-mediated KD in Fujioka AML cells of FTO-lncAML using two shRNAs (KD1 and KD2) targeting exon 1 (Figure 4F), thereby avoiding targeting exon 2 which is shared with some full-length FTO transcripts. This evidence concerns the gene IRX3 and acute myeloid leukemia.